Lack of Clarity Continues Pushing Affimed Lower
Insights - Affimed announced a rather disappointing update yesterday. There was not much clarity shared and it seemed like AFM24 was seeing more data delays. The main … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Karuna Latest Phase 3 Data Strengthens Upcoming NDA
Insights - Yesterday Karuna (KRTX) reported data on the third positive registrational trial, announcing that the trial met its primary endpoint. With three positive registrational trials reported … Continue Reading
Premium
Government Steps In To Save Depositors, Many Bio Companies
Insights - The wild weekend was followed by an eventful Monday, especially for the biotech world. The SVB fiasco saw a solution that was a relief for … Continue Reading
Read now
Silicon Valley Bank (SVB) Collpase Impacts Bio Markets
Insights - Silicon Valley Bank’s collapse has caused a ripple amongst the biotech world as the bank did business with about half of American tech and biotech … Continue Reading
Premium
Day One (DAWN) To Present Updated Results Ahead of NDA Submission
Insights - Day One’s Drug Ready for NDADay One Pharma (DAWN) is developing tovorafenib (DAY101), an oral pan-RAF inhibitor for pediatric low-grade gliomas (pLGG). Despite being the … Continue Reading
Premium
aTyr (LIFE) Financing Makes It Late 2023 Story
Insights - aTyr (LIFE) announced a financing yesterday which diluted the company by approximately 45%. LIFE offered 22.225M shares of stock at a price of $2.25 to raise … Continue Reading
Premium
Addex Gives Vague Update on Q1 Data Readout
Insights - This morning, Addex (ADXN) announced that Janssen has completed the enrolment of Part 1 of their Phase 2 clinical study of ADX71149 in epilepsy. Data … Continue Reading
Premium